ArticleForensic toxicology2026
Characterization of fluvoxamine degradation products in postmortem blood by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry.
Article in Forensic toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeFluvoxamine (FLV) is a selective serotonin reuptake inhibitor primarily used to treat obsessive-compulsive disorder. In Japan, FLV is linked to lethal intoxication and suicide cases. Therefore, it is important to establish its exact concentration in postmortem (PM) blood. It has been reported that blood FLV concentration decreases over time. In this study, we aimed to clarify the mechanisms underlying changes in FLV concentration in human blood over time.
methodsWe examined whether FLV underwent hydroxylation and/or oxidation in a Fenton reaction mixture containing FeCl2, hemoglobin (Hb), or hydrogen peroxide (H2O2) after incubating at 37 °C for 24 h. In addition, we measured FLV and its degradation products in human blood by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry.
resultsMass spectrometric result indicated the formation of (E)-N-(2-(((5-methoxy-1-(4(trifluoromethyl)phenyl)pentylidene)amino)oxy)ethyl)formamide (FLV-CHO), (E)-5-hydroxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one-O-(2-aminoethyl)oxime (FLD), and (E)-5-(hydroxymethoxy)-1-(4-(trifluoromethyl)phenyl)pentan-1-one-O-(2-aminoethyl)-oxime (FLV-OH) in the reaction mixture. In addition, FLV-CHO concentration in human blood was strongly correlated with percentage FLV degradation relative to its initial concentration.
conclusionsOur results indicate that FLV-CHO, formed by Hb/H2O2-mediated FLV degradation in blood, is a potential biomarker for correcting FLV concentration in PM blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.